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ABSTRACT
Although cannabis- based products for medicinal use are 
now legal in the UK, it is still challenging for patients to 
gain access, and only very few National Health Service 
prescriptions have been written to date. This paper 
attempts to make sense of why the UK lags behind so 
many other countries which also have legalised medical 
cannabis. From consulting with parents and patients, 
prescribers, pharmacists and decision- makers it seems 
that there are a series of distinct barriers to prescribing 
that need to be overcome in order to improve patient 
access to medical cannabis in the UK. These include 
concerns about the perceived lack of scientific evidence. 
To alleviate these concerns, we highlight the importance 
of patient- centred approaches including patient- reported 
outcomes, pharmacoepidemiology and n=1 trials, which 
can contribute to the development of the evidence base 
for medical cannabis. We hope that this paper will help 
policymakers and prescribers understand the challenges 
to prescribing and so help them develop approaches to 
overcome the current situation which is detrimental to 
patients.
INTRODUCTION
In November 2018 when the UK made 
cannabis- based products for medicinal use 
(CBPMs) legal most people assumed these 
would immediately be made available to 
patients, but they were wrong. In the year 
since almost no National Health Service 
(NHS) prescriptions have been issued1 and 
less than a hundred have been made avail-
able from private providers at a cost of at 
least £1000 a month.2 For these reasons, 
some parents of children with severe epilepsy 
continue to go overseas to get their chil-
dren access to the only treatment which has 
proven to be effective for their condition, 
that is, a cannabinoid medication. Moreover, 
the vast majority of the estimated 1.4 million 
medical cannabis users3 source from the 
black market with its problems of illegality, 
unknown quality, content and provenance. 
Given the substantial evidence of utility of 
CBPMs in many disorders as identified in the 
US National Academy of Sciences review in 
20174 this failure of delivery in the UK seems 
odd and, to many, inexcusable.
CONCERNS ABOUT PERCEIVED LACK OF EVIDENCE
Statements such as ‘insufficient evidence of 
efficacy’ or ‘it is too dangerous’ are common 
and used even in the face of strong personal 
evidence from patients that CBPMs work and, 
in many cases, can be life- changing and well 
tolerated. Many doctors fail to include the 
evidence of the patient’s lived experience 
and cite the lack of placebo- controlled trials 
in every possible indication for their hesita-
tion to prescribe. While tens of thousands 
of individual patient reports of the thera-
peutic value of CBPMs as in the Canadian 
and Minnesota databases5 6 do not equate 
to the so- called gold- standard double- blind 
randomised controlled trial (RCT) level of 
proof, they are highly suggestive of a pattern 
of evidence which should be taken seriously 
rather than summarily dismissed. These 
large- scale databases could be further inter-
rogated and systematically analysed to collate 
patient- reported outcomes (PROs) and other 
existing evidence for peer- reviewed publi-
cations. In the UK, Drug Science recently 
launched Project TWENTY21, the largest 
national medical cannabis registry in Europe, 
with the aim to create a structured body of 
Strengths and limitations of this study
 ► There are a series of distinct barriers to prescribing 
medical cannabis that need to be overcome in order 
to improve patient access in the UK.
 ► Concerns about the perceived lack of randomised 
controlled trial evidence are misplaced as many 
patient- centred approaches including patient- 
reported outcomes, pharmacoepidemiology and 
n=1 trials can be applied.
 ► Thousands of UK patients self- medicating with illicit 
cannabis- based products for medicinal use and the 
international database evidence suggest this new 
class of drugs offers a significant advance in treat-
ment for many in whom current medicines are either 
ineffective or poorly tolerated.
 ► We hope that this paper will help policymakers and 
prescribers understand the challenges to prescrib-
ing and so help them develop approaches to over-
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evidence for the effectiveness and tolerability of medical 
cannabis for a broad range of conditions (https:// drug-
science. org. uk/ project- twenty21/). Moreover, Drug 
Science is also currently working on audits using existing 
data of patients with epilepsy prescribed medical cannabis, 
showing, for example, a clear reduction of seizures after 
medical cannabis use.
The major criticism of the lack of placebo- controlled 
trials is misplaced. Prescribers often mistakenly state that 
without these they cannot prescribe. However, there are 
over 50 medicines or indications that have been licensed 
by Food and Drug Administration and/or European 
Medicines Agency between 1999 and 2014 without RCT 
data.7
Moreover, the ex- head of National Institute for Health 
and Care Excellence (NICE) and the Medicines and 
Healthcare products Regulatory Agency, Sir Michael 
Rawlins, challenged this RCT preconception in the 2008 
Harvean Oration, highlighting that:
Randomised controlled trials (RCTs), long regarded 
at the ‘gold standard’ of evidence, have been put on 
an undeserved pedestal. Their appearance at the top 
of ‘hierarchies’ of evidence is inappropriate; and hi-
erarchies, themselves, are illusory tools for assessing 
evidence. They should be replaced by a diversity of 
approaches that involve analysing the totality of the 
evidence- base.8
Placebo- controlled double- blind trials are clearly a very 
important element of medicine where their primary role 
is to provide evidence for companies to get a marketing 
authorisation. Such trials are done in tightly selected 
patient groups that are not representative of the average 
patient who often has many different medical comorbid-
ities. Therefore, even when such trials are positive, they 
are only suggestive of efficacy in the wider patient groups 
and other approaches such as effectiveness trials or clin-
ical audits are required to properly estimate real- world 
value to individual patients.
Of these new approaches, PROs are probably the most 
significant development. These have received immense 
investment from the US National Institutes of Health 
(NIH) and many new scales have been developed for this 
purpose. PRO measures are now required as elements of 
outcome measures for clinical trials funded by the NIH in 
the USA (https:// commonfund. nih. gov/ promis/ index. 
PROs put more emphasis on the patient’s life and well- 
being and have been shown to be more sensitive to the 
effects of medical cannabis than traditional symptom- 
based measures. For example, a large recent naturalistic 
German study on pain syndromes using PROs found 
adding a CBPM very significantly improved outcomes 
in patients with neuropathic pain.9 Other recent papers 
showing real- world benefits from CBPMs using patient 
reports have been reported in Parkinson’s disease10 and 
autism.11 NICE has developed a cadre of expert patients to 
advise them of the patients’ perspective (https://www. scie- 
socialcareonline. org. uk/ the- expert- patients- rogramme/ 
r/ a1CG0000000GNbcMAG) although it is not apparent 
if this includes a patient with experience of medical 
cannabis. Progress in this direction has led to the setting 
up of a special centre in Cambridge for patient- led 
research in the clinical trials unit: https://www. cuh. nhs. 
uk/ clinical- trials/ cambridge- clinical- trials- unit- cctu/ 
patient- led- research- hub.
Pharmacoepidemiology and, specifically, observational 
research is another recent patient- centred approach to 
study the effectiveness of real- world medication.12 Advan-
tages include the availability of large patient samples, 
coverage of under- researched subpopulations in their 
naturalistic conditions and lower costs than RCTs.13 The 
limitation of the non- randomised nature of treatment 
selection can be addressed by including comparison 
groups, or through the triangulation of multiple analyt-
ical approaches to improve confidence in inferred causal 
relationships.
With many clinicians demanding better and faster 
evidence to inform their decisions around prescribing 
CBPMs, these newer approaches offer potential solutions 
to the lack of RCTs. Indeed, in line with rapid develop-
ments in data resources and analytical techniques, many 
guidelines are now beginning to include evidence from 
robust observational pharmacoepidemiological studies 
alongside RCTs.13
But even more important are the n=1 trials, for these 
are the core of medical practice since every time a medicine 
is prescribed an n=1 experiment is being conducted. In 
some patients the experiment works and in others it fails, 
the patient either does not respond or the adverse effects 
outweigh the therapeutic benefit. One might therefore 
expect that doctors would welcome patients who have 
conducted successful self- treatment with cannabis since 
it is almost certain that prescribing medical cannabis 
to these will work, providing a therapeutic win for both 
patient and prescriber.
The resurrection of CBPMs following its banning by the 
United Nations Conventions is directly attributable to n=1 
trials conducted in children with intractable epilepsy. The 
first patient was Charlotte Web in the USA who inspired 
UK parents of children with similar epilepsies notably 
Alfie Dingley and Billy Caldwell. These children were 
facing death and/or brain damage from multiple seizures 
resistant to licensed treatments and CBPMs restored them 
to close to normality and also allowed them to come of 
other medicines. In the case of Billy, the proof of thera-
peutic efficacy was dangerously established by the confis-
cation of his medical cannabis by UK customs which led 
to a life- threating episode of status epilepticus requiring 
admission to intensive care. The public outcry over such 
callous treatment by the UK government was the imme-
diate cause of the rescheduling of medical cannabis in 
November 2018.
In scientific terms Billy was the subject of an A- B- A 
design, one of the most powerful methodologies for 
examining a medical intervention. The UK government 
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any prescriber resist similar claims in their patients, partic-
ularly if they had seen their own previously prescribed 
treatments fail? In such cases to deny a patient a CBPM 
simply because they are using an ‘illegally’ sourced prepa-
ration is illogical and could be construed as being uneth-
ical. Germany took this view when deciding to make 
medical cannabis available. The General Medical Council 
(GMC) guidance on good medical practice makes it clear 
that all registered doctors must take into account and 
respect patients’ views and experience.
Scientific support for ABA trials is well established in 
educational, behavioural and psychological assessment 
but less so in medical research.14 15 An ABA(B) trial design 
is well suited for determining whether medical cannabis 
is efficacious. Bayesian analysis can also combine separate 
ABA(B) results from different populations of patients, 
such as cannabis and non- cannabis users, stratified as 
suggested by experts whose experience has identified 
possible confounding variables.16 This approach is known 
as multilevel regression and poststratification.17
WHAT ARE THE REASONS FOR THIS RESISTANCE?
One source of this resistance is that because CBPMs are 
patient driven, to welcome them would be an admission 
that the patients are more knowledgeable than the doctor. 
Despite over a decade of demands by the Department of 
Health and Social Care (DHSC) for patients to have a say 
in medical practice in the UK, there has been little prog-
ress. In this debate it is usually forgotten that cannabis was 
a licensed medicine in the UK before 1971. So why does 
the government not just reissue the license that applied 
then? Phenergan and chloral hydrate have continued to 
be available in the UK since that time despite no double- 
blind clinical trial data and chloral is sometimes used as 
an antiepilepsy treatment in the children with epilepsy 
who are denied CBPMs!
Another factor is the ‘not invented here’ syndrome. 
UK prescribers often say they only trust data collected 
here; an attitude justified by our high- quality health tech-
nology assessment processes especially NICE. However, to 
ignore data from other countries in a field as complicated 
as medical cannabis likely distorts the truth. Medical 
cannabis has been available for over a decade in many 
states in the USA and there are nearly 20 000 patients 
on the Minnesota database, providing detailed data on 
various conditions and PROs since 2015. These data 
should be interrogated and formally published as a way 
to accelerate clinically relevant information to potential 
prescribers as the Health Secretary Matt Hancock stated 
in July 2019.18
This statement calls into question the current DHSC 
rule that medical cannabis must be considered a ‘Special’. 
The challenges of Specials to prescribers are not trivial 
and include:
1. Organisational bureaucracy and the subsequent delay 
of prescribing, approval and supply.
2. Transferring a patient between one sector and anoth-
er, especially where, for example, primary care will not 
continue prescribing of a superficially expensive spe-
cial or unlicensed product.
3. Local secondary and primary care services having dif-
ferent rules and guidance, particularly about prescrib-
ing unlicensed medicines.
4. Responsibility for prescribing—a licensed product’s 
manufacturer is accountable for any untold harm if 
the product is used within the license, but with an un-
licensed product or Special the prescriber assumes re-
sponsibility for any harm that occurs, unless it can be 
directly attributed to a defect in the actual product.
These complexities do give some support to doctors’ 
perception of prescribing as too difficult. Moreover, the 
DHSC has made cannabis a special ‘special’ as prescribing 
requires a special pink pad that has to be ordered. Why 
such constraints are required is unclear given the estab-
lished safety of cannabis medicines, but they are problem-
atic for the prescriber and likely deter use.
Most UK doctors have no experience of medical 
cannabis and comments like ‘I don’t know what to 
prescribe’ are often heard. Though understandable they 
reflect poorly on a profession which generally welcomes 
engaging with new therapeutics; until medical cannabis 
came along prescribers were rarely fearful of new thera-
peutics. Moreover, new is not really a credible term given 
the decade of CBPMs in USA, Canada and the Nether-
lands, and its subsequent publications on the practical 
considerations in medical cannabis administration and 
dosing.19 The 1998 House of Lords report on medical 
cannabis provided clear evidence on efficacy and value of 
medical cannabis.20 Both delta-9- tetrahydrocannabinol 
(THC) (eg, as nabilone) and a mixture of delta-9- THC 
and cannabidiol (as Sativex, made from whole plant 
extracts) have been licensed medicines in the UK for over 
a decade. The decision to move cannabis to Schedule 
2 was made on the basis that there were adequate data 
that it was a medicine.21 While there is little in the way 
of teaching on medical cannabis in the undergrad or 
postgrad medical curricula, the past couple of years have 
seen an increasing amount of medical cannabis educa-
tional programmes of varying standards. Especially for 
clinicians it is essential to be able to find non- biased 
educational programmes, highlighting the need for 
accredited training to be made available. Drug Science 
is currently offering free online teaching courses on 
medical cannabis and is also working on the develop-
ment of accredited courses together with the Society for 
the Study of Addiction.
Perhaps one reason for resistance to CBPMs is that for 
nearly 50 years the medical profession focused on the 
risks of cannabis with extreme claims of harms, including 
male sterility, lung cancer and schizophrenia. Though 
these have now been largely debunked and were gener-
ally the result of recreational rather than prescribed 
medical use, many practitioners may not know this. Even 
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a drug that has been vilified for decades as toxic. Here 
education is the solution.
Furthermore, patients self- medicating are often using 
the same illicitly sourced products as recreational users, 
making differentiation between uses challenging for clini-
cians. For both patient and doctor, access to fully regu-
lated products could ensure a known dose and a quality 
and content that can actually be monitored.
THE PHARMACY PERSPECTIVE
Pharmacists (especially at Clinical Commissioning Group 
level) and medical prescribing advisors also play a signif-
icant role, often through area prescribing committees 
(APCs). Pharmacy advisors tend to think of themselves 
as guardians of the public purse in relation to medicines 
prescribing. Their default position is usually to resist the 
cost implications of new medicines by blocking approval 
to local prescribing lists. Here the resistance is often 
derived from a misplaced focus of prescription costs with 
the cost benefits of saving in other medicines and inter-
ventions being ignored; for example, medical cannabis 
can reduce the use of strong opioids,22 23 and lower 
prescription costs.24
We suggest that APCs should give CBPMs a fair chance 
by:
 ► Ensure better training locally.
 ► Agreeing with the relevant consultants, for example, 
pain or neurology clinics, a specified number of 
patients each year.
 ► Factor in the costs of the alternatives, for example, 
opioid overuse (due to lack of efficacy for many 
pains), benzodiazepines and pregabalin/gabapentin 
overmedication or self- medication.
 ► Take genuine notice of testimonies from patients, 
who will not be diverting CBPMs because they need it.
 ► Remember that generic substitution of CBPMs is 
challenging as all products have different ratios of 
THC and Cannabidiol (CBD) and may give different 
actions.
 ► Remember that there are many CBPMs with low THC 
or absent of THC. Also, the common routes of inges-
tion (ie, oral oil/capsule) make it unlikely for patients 
to have immediate intoxication effects.
 ► In order to clarify cost implications of prescribing 
CBPMs, it is essential to conduct a full health 
economic analysis. Quality cost savings analyses are 
lacking at present and will be important for govern-
ments to enable active changes.
CONCLUSIONS
The many thousands of UK patients self- medicating 
with non- regulated CBPMs and the international data-
base evidence suggest these new medical products offer 
a significant advance in treatment for many in whom 
current medicines are either ineffective or poorly toler-
ated. They also offer the potential of significant cost 
savings to the NHS in terms of reduced hospital stays 
and less prescribing of other medicines particularly 
opioids for chronic pain. The failure of the medical and 
pharmacy professions to embrace CBPMs despite their 
being made ‘legal’ over 18 months ago is a great worry 
to patients and will already likely have led to preventable 
deaths from conditions such as epilepsy. We hope that this 
paper will help policymakers and prescribers understand 
the challenges to prescribing and so help them develop 
approaches to overcome the current highly unsatisfactory 
situation.
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